NextTrip, Inc., a technology-driven travel company, develops an integrated travel booking and media platform to connect leisure, group, and business travelers in the United States and internationally. It operates in two segments, Travel and Media. The Travel segment offers NXT2.0, a travel booking engine that supports direct-to-consumer and advisor-assisted booking across leisure, luxury, cruise, group, and business travel verticals; Five Star Alliance for luxury and cruise bookings; TA Pipeline, a group-travel agency platform that provides end-to-end solutions for conferences, conventions, destination weddings, and affinity groups; JournyGO, an agentic AI-powered consumer engagement and booking ecosystem; and Travel Magazine Pro, a digital editorial, advisor-engagement, and travel-commerce platform. Its Media segment includes JOURNY.tv, a travel media network, as well as TravelMagazine.com, an online travel publication that offers articles, guides, destination inspiration, hotel and restaurant recommendations, and general travel advice. The company was formerly known as Sigma Additive Solutions, Inc. and changed its name to NextTrip, Inc. in March 2024. NextTrip, Inc. is based in Santa Fe, New Mexico.
Research context
NextTrip Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Consumer Cyclical
- Industry
- Travel Services
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 7 months ago
Neurotrope, Inc is currently in a long term downtrend where the price is trading 16.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Neurotrope, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 11.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 19.1% to $-3M since the same quarter in the previous year.
Based on the above factors, Neurotrope, Inc gets an overall score of 1/5.